Carisoprodol

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 317373

CAS#: 78-44-4

Description: Carisoprodol is discontinued (DEA controlled substance). Carisoprodol is a centrally acting skeletal muscle relaxant of the carbamate class and produces all the effects associated with barbiturate receptor ligands. It is slightly soluble in water and freely soluble in ethanol, chloroform and acetone. The drug's solubility is practically independent of pH. Although carisoprodol has significant pharmacological activity, its benefit in therapy is likely due mostly to the meprobamate metabolite as meprobamate remains in the system significantly longer and reaches a higher peak plasma concentration than the parent drug a few hours following administration. This is further evidenced by carisoprodol's ability to maintain relevant benefits when administered 3-4 times a day despite its short half-life of only two hours.


Chemical Structure

img
Carisoprodol
CAS# 78-44-4

Theoretical Analysis

MedKoo Cat#: 317373
Name: Carisoprodol
CAS#: 78-44-4
Chemical Formula: C12H24N2O4
Exact Mass: 260.17361
Molecular Weight: 260.32996
Elemental Analysis: C, 55.36; H, 9.29; N, 10.76; O, 24.58

Size Price Shipping out time Quantity
Inquire bulk and customized quantity

Pricing updated 2021-02-27. Prices are subject to change without notice.

Carisoprodol is discontinued. (DEA controlled substance.)

Synonym: Carisoprodol, Soma, Sanoma, Carisoma

IUPAC/Chemical Name: [2-(carbamoyloxymethyl)-2-methylpentyl] N-propan-2-ylcarbamate

InChi Key: OFZCIYFFPZCNJE-UHFFFAOYSA-N

InChi Code: InChI=1S/C12H24N2O4/c1-5-6-12(4,7-17-10(13)15)8-18-11(16)14-9(2)3/h9H,5-8H2,1-4H3,(H2,13,15)(H,14,16)

SMILES Code: O=C(OCC(C)(COC(N)=O)CCC)NC(C)C

Appearance:
White crystalline powder.

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO, not in water

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code:
2934.99.9001

Handling Instructions:

Preparing Stock Solutions

The following data is based on the product molecular weight 260.32996 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Masoner JR, Kolpin DW, Furlong ET, Cozzarelli IM, Gray JL. Landfill leachate
as a mirror of today's disposable society: Pharmaceuticals and other contaminants
of emerging concern in final leachate from landfills in the conterminous United
States. Environ Toxicol Chem. 2015 Nov 12. doi: 10.1002/etc.3219. [Epub ahead of
print] PubMed PMID: 26562222.

2: Paulozzi LJ, Strickler GK, Kreiner PW, Koris CM. Controlled Substance
Prescribing Patterns - Prescription Behavior Surveillance System, Eight States,
2013. MMWR Surveill Summ. 2015 Oct 16;64(9):1-14. doi: 10.15585/mmwr.ss6409a1.
PubMed PMID: 26469747.

3: Sullivan MD. What are we treating with opioid and sedative-hypnotic
combination therapy? Pharmacoepidemiol Drug Saf. 2015 Aug;24(8):893-5. doi:
10.1002/pds.3821. Epub 2015 Jun 22. PubMed PMID: 26098538.